Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014
March 06 2014 - 3:05PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded multicellular therapies for the treatment
of severe chronic cardiovascular diseases, announces the following
webcast:
What: |
Aastrom Biosciences, Inc., Fourth Quarter
2013 Investor Call |
|
|
When: |
Thursday, March 13, 2014 at 4:30 pm
(EDT) |
|
|
Where: |
http://investors.aastrom.com/events.cfm |
|
|
How: |
-- The conference call will be available live
in the Investors section of the Aastrom website at
http://investors.aastrom.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
-- To participate in the live call by
telephone, please call (877) 312-5881 and reference Aastrom
Biosciences fourth quarter 2013 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237-1173. |
If you are unable to participate during the live call, the
webcast will be available at
http://investors.aastrom.com/events.cfm until March 13,
2015. A replay of the call will also be available until 11:59
pm (EDT) on March 17, 2014 by calling (855) 859-2056, or from
outside the U.S. at (404) 537-3406. The conference ID is
5780779.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
Phase 2b clinical trial in patients with advanced heart failure due
to ischemic dilated cardiomyopathy. For more information, please
visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning future purchases pursuant
to the purchase agreement with Lincoln Park, clinical trial plans
and progress, objectives and expectations, clinical activity
timing, intended product development, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with the
closing of the offering described herein, Aastrom's intended use of
proceeds in connection with the offering, clinical trial and
product development activities, regulatory approval requirements,
competitive developments, and the availability of resources and the
allocation of resources among different potential uses. These
and other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K for the year ended
December 31, 2012, filed with the Securities and Exchange
Commission ("SEC") on March 18, 2013, Quarterly Reports on
Form 10-Q and other filings with the SEC. These
forward-looking statements reflect management's current views and
Aastrom does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date of this release except as
required by law.
CONTACT: Media contact:
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024